Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, United Kingdom with an additional office in Boston, Massachusetts. As of June 24, 2026, Centessa Pharmaceuticals plc operates as a subsidiary of Eli Lilly and Company.
Часто задаваемые вопросы
В каком секторе работает CENTESSA PHARMACEUTICALS (260)?
CENTESSA PHARMACEUTICALS относится к сектору Здравоохранение.
Какова текущая цена акций CENTESSA PHARMACEUTICALS (260)?
По последним данным, цена акций CENTESSA PHARMACEUTICALS составляет 34,60 €, предыдущее закрытие — 34,60 €.
Выплачивает ли CENTESSA PHARMACEUTICALS (260) дивиденды?
Нет, CENTESSA PHARMACEUTICALS не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у CENTESSA PHARMACEUTICALS (260)?
У компании CENTESSA PHARMACEUTICALS бета 1.108, что означает, что её волатильность примерно соответствует рыночной.
